

22 April 2024

Company Announcements  
ASX Limited

**Cleansing Notice – Section 708A (5)(e) of the Corporations Act 2001**

Bioxyne Limited gives this notice pursuant to Section 708A(5)(e) of the Corporations Act in relation to the issue of 145,000,000 shares as set out in the Appendix 2A dated 22 April 2024.

The Company issued 145,000,000 shares at \$0.01 per share in a capital raise outlined in the ASX announcement dated 18 April 2024, without disclosure, under Part 6D.2 of the Corporations Act.

The Company, as at the date of this notice, has complied with:

- (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
- (b) section 674 of the Corporations Act.

As at the date of this notice, there is no information to be disclosed that is “excluded information” within the meaning of section 708A(7) and 708A (8) of the Corporations Act.

This announcement has been approved by the Board.

Guy Robertson  
Company Secretary

This announcement has been approved for release by the Board.

**For further information contact:**

Guy Robertson  
Company Secretary  
[guy@bioxyne.com](mailto:guy@bioxyne.com)

### **About Bioxyne**

Bioxyne Limited (ASX:BXN) is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

### **About Breathe Life Sciences (BLS)**

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and licensed manufacturer, sponsor, importer and exporter of controlled substances (S3, S4, S8) in Australia.

BLS was founded in 2018 and has quickly expanded into a multi national business focused on alternative therapeutics and investigational medicines. Our corporate head office is in Sydney, and our operations extend to licensed manufacturing, warehousing, import/export, sales and distribution centers in the Gold Coast (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

Our business model is focused on manufacture of final dose form / finished products, sales and distribution in each of the territories we serve. We work with raw materials and API suppliers in 5 continents and are a market leader in manufacturing scope and quality.

The BLS logo is derived from a Japanese Maple Leaf, symbolising health, happiness and a long life well lived. While the Japanese Maple is not a medicinal plant, our company purpose is to redefine medicine by taking a holistic approach to healthcare for a healthier and happier tomorrow.

Outside of Australia the BLS Group operates a health and wellness products and brands business focussed on naturally derived active nutraceuticals, wellness and lifestyle supplements and cannabidiol (CBD) based novel foods. It primarily operates in the UK, Europe and Japan, and engages in the following activities:

- (a) owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand – Dr Watson is an internationally recognized health, lifestyle, and prescription products brand. Dr Watson products consist of cannabis-based food supplements, lifestyle products, cosmetics, functional mushrooms and nootropics, and prescription medicines in Australia;
- (b) contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe;
- (c) white label manufacture of third-party wellness and supplements brands in Japan, UK and Europe in company-owned facilities;
- (d) research and development for third party customers; and
- (e) direct sales via online and wholesale sales of BLS-owned consumer brands, such as Dr Watson® ([drwatsoncbd.com](http://drwatsoncbd.com), [nolcbn.com](http://nolcbn.com), [drwatsoncbd.de](http://drwatsoncbd.de))

Corporate: <https://bioxyne.com>

Australia: <https://bls.com.au>; <https://blsclinics.com.au>

International: <https://breathelifesciences.com>

Dr Watson (UK and EU only): [drwatsoncbd.com](http://drwatsoncbd.com); [drwatsoncbd.de](http://drwatsoncbd.de); [nolcbn.com](http://nolcbn.com)